

Colorectal Cancer (CRC)

**A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)**

**Trial Status**  
Completed

**Trial Runs In**  
23 Countries

**Trial Identifier**  
NCT02291289 2014-001017-61  
MO29112

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This randomized, multi-center, active-controlled, open-label, parallel-group study will investigate the efficacy and safety of biomarker-driven maintenance treatment for first-line mCRC. Participants with mCRC are eligible for entry and cannot have received any prior chemotherapy in the metastatic setting. The entire study duration is anticipated to be approximately 7.5 years.

**Hoffmann-La Roche**  
Sponsor

**Phase 2**  
Phase

---

**NCT02291289 2014-001017-61 MO29112**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No

---